Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07195513 · ClinicalTrials.gov registry record · NA

Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services

A NA study of Advanced Cancer and Metastatic Cancer (Different Solid Tumour Types), sponsored by Dartmouth-Hitchcock Medical Center.

Recruiting
Registry status
NA
Development phase
90
Enrollment target
1
Study location

NCT07195513: Recruiting NA study of Advanced Cancer and Metastatic Cancer (Different Solid Tumour Types), sponsored by Dartmouth-Hitchcock Medical Center.

NCT07195513 is a NA study of Advanced Cancer and Metastatic Cancer (Different Solid Tumour Types) that is actively recruiting participants, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 90 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07195513, a NA study of Advanced Cancer and Metastatic Cancer (Different Solid Tumour Types), is actively recruiting participants, sponsored by Dartmouth-Hitchcock Medical Center.

RECRUITING
Registry status
NA
Development phase
90 participants
Enrollment target
1
Study location

Study Summary

This study is testing whether electronic surveys can help patients with advanced cancer report their symptoms and care needs so their doctors can connect them to palliative/supportive care services sooner. The goal is to see if this approach can make it easier for patients to get support for symptoms, quality of life, and other needs during cancer treatment.

Primary Outcome

Feasibility will be assessed as a composite of three prespecified components, each summarized as a proportion with 95% confidence intervals: Enrollment: Proportion of eligible patients who provide informed consent and are randomized. Retention: Proportion of randomized patients who complete the FACT-G at 12 weeks \[primary feasibility outcome\] and 24 weeks. Intervention Compliance: Weekly ePRO symptom surveys: Longitudinal compliance quantified as the proportion of participants who self-rep

Interventions

  • BEHAVIORAL ePRO-Directed Referral and Navigation to Palliative/Supportive Care
  • OTHER ePRO Symptom Monitoring with Usual Palliative Care Referral

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock Medical Center - Lebanon

Trial Details

FieldValue
Enrollment Target 90 participants
Start Date 2026-02-25
Est. Completion 2028-12
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What NCT07195513 shows while recruiting

NCT07195513 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (63% lower).

The record links to 4 conditions, with Advanced Cancer appearing as the primary indexed condition, and to 2 interventions - of which ePRO-Directed Referral and Navigation to Palliative/Supportive Care is the first listed.

NCT07195513 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT07195513 about?

NCT07195513 is a clinical study titled "Electronic Patient Reporting of Symptoms and Unmet Needs to Connect Patients With Advanced Cancer to Palliative Care Services". This study is testing whether electronic surveys can help patients with advanced cancer report their symptoms and care needs so their doctors can connect them to palliative/supportive care services sooner. The goal is to see if this approach can make it easier for patients to get support for symptom...

What is the current status of trial NCT07195513?

This trial is currently recruiting. It is a NA study. The enrollment target is 90 participants. The study started on 2026-02-25. Estimated completion is 2028-12.

What conditions does trial NCT07195513 study?

This clinical trial studies the following conditions: Advanced Cancer, Metastatic Cancer (Different Solid Tumour Types), Palliative Care Referral, Palliative Care, Health Services.

What interventions are being tested in trial NCT07195513?

The interventions under investigation include: ePRO-Directed Referral and Navigation to Palliative/Supportive Care (BEHAVIORAL), ePRO Symptom Monitoring with Usual Palliative Care Referral (OTHER).

Who is sponsoring clinical trial NCT07195513?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07195513 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Advanced Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07195513's enrollment target sits among peer trials

90 62nd of 122 higher than 61 of 122 other Advanced Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02521311 · 90 participants · Phase 2

    Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)

  • NCT02939573 · 90 participants · Phase 2

    A Randomized Multicenter Study for Isolated Skin Vasculitis

  • NCT03128879 · 90 participants · Phase 2

    Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

  • NCT03184038 · 90 participants · NA

    Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT07195513, the US trial registry maintained by the National Library of Medicine. NCT07195513 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.